Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Allergan Seeks Opportunities To Dominate In Key Therapeutic Areas

This article was originally published in Scrip

Executive Summary

Allergan plc is known as one of the most acquisitive players in the pharmaceutical industry, but the company asserted its commitment to in-house and early-stage innovation as well during R&D Day presentations on Nov. 4, reflecting a strategy similar to its potential acquirer Pfizer Inc.

You may also be interested in...



Allergan's Fishing For Deals, But Don't Expect A Big Catch

Allergan PLC will use its $36bn in after-tax cash and equity from the sale of its generics business to Teva Pharmaceutical Industries Ltd. to reduce debt, buy back shares of its stock, and to acquire companies or assets, but don't expect Allergan to catch any big fish in its dealmaking net.

ARCH Cites Stability Of Long-Term Investors In Raising $3bn Fund

ARCH Venture Partners brought in $2.975bn for its latest fund to give additional long-term investors a place at the table as the VC firm creates, builds and supports new early-stage biotechnology start-ups. 

ReCode Raises Another $120m To Broaden LNP Delivery Of Genetic Medicines

The company’s lipid nanoparticle technology can deliver mRNA, gene editing and other cargoes to multiple cell and organ types. ReCode aims to expand its pipeline beyond lung diseases.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC030234

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel